Results 1 to 10 of about 146,093 (222)

Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin [PDF]

Microbial Cell, 2014
The human pathology Wilson disease (WD) is characterized by toxic copper (Cu) accumulation in brain and liver, resulting in, among other indications, mitochondrial dysfunction and apoptosis of hepatocytes.
Pieter Spincemaille, Gursimran Chandhok, Andree Zibert, Hartmut Schmidt, Jef Verbeek, Patrick Chaltin, Bruno P.A. Cammue, David Cassiman, Karin Thevissen   +8 more
doaj   +7 more sources

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy. [PDF]

J Renin Angiotensin Aldosterone Syst, 2020
Introduction: The aims of this study were to assess the renal expression of angiotensin II type 1 receptor (AT1R), angiotensin II type 2 receptor (AT2R), and MAS receptor in human type 2 diabetic nephropathy (DN). Materials and methods: In total, 115 patients diagnosed with DN by renal biopsy were enrolled in this study.
Ma YP, Yang Y, Jiang SM, Liu L, Zhang Z, Wang YN, Zou GM, Li WG.   +7 more
europepmc   +5 more sources

Clinical Comparative Trials of Angiotensin II Type 1 (AT 1 )-Receptor Blockers [PDF]

Blood Pressure, 2001
Three characteristics of antihypertensive medication are pivotal in therapy for a patient with hypertension: potency and efficacy, duration of action, and the incidence of side-effects. The relatively new class of AT1-receptor blockers all display placebo-like tolerability and, as a class, their antihypertensive efficacy compares well with other ...
Peter Meredith
semanticscholar   +4 more sources

Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications. [PDF]

Neurotox Res, 2017
Angiotensin II receptor blockers (ARBs) are one of the most frequently recommended antihypertensive drugs. Apart from their activity towards the circulatory system, ARBs also penetrate the blood-brain barrier and display neuroprotective effects. Kynurenic acid (KYNA) is an endogenous metabolite of tryptophan produced by kynurenine aminotransferase II ...
Zakrocka I, Targowska-Duda KM, Wnorowski A, Kocki T, Jóźwiak K, Turski WA.   +5 more
europepmc   +5 more sources

Comparative Efficacy of Angiotensin II Type 1 Receptor Blockers Against Ventilator‐Induced Diaphragm Dysfunction in Rats [PDF]

Clinical and Translational Science, 2021
Mechanical ventilation (MV) is a life‐saving intervention for many critically ill patients. Unfortunately, prolonged MV results in the rapid development of inspiratory muscle weakness due to diaphragmatic atrophy and contractile dysfunction (termed ...
Stephanie E. Hall, Bumsoo Ahn, Ashley J. Smuder, Aaron B. Morton, J. Matthew Hinkley, Michael P. Wiggs, Kurt J. Sollanek, Hayden Hyatt, Scott K. Powers   +8 more
doaj   +2 more sources

Angiotensin II type 1 receptor blocker-induced immune thrombocytopenia: a case report [PDF]

Journal of Medical Case Reports, 2013
The development of thrombocytopenia after a dose increase in losartan and subsequently after switching the patient to valsartan is reported.A 61-year-old Caucasian man presented with epistaxis and gingival bleeding of three weeks duration. Laboratory evaluation revealed a hemoglobin level of 144g/L, a leukocyte count of 16.2×109 cells/L (72.51 ...
Dhiren Patel, Nikhil Bilkha, David Schnee   +2 more
openalex   +3 more sources

Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents. [PDF]

Cardiol J, 2023
Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Park SH, Kim S, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y.   +12 more
europepmc   +3 more sources

Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers. [PDF]

Eur J Prev Cardiol, 2022
Sarzani R, Giulietti F, Pentima CD, Giordano P, Spannella F.   +4 more
europepmc   +3 more sources

Unique mode of binding between angiotensin II type 1 receptor and its blockers

Clinical and Experimental Hypertension, 2019
BACKGROUND: We hypothesized that the 5-oxo-1,2,4-oxadiazole moiety of azilsartan (AZL), which represents a small difference in the molecular structures of AZL and candesartan (CAN) [angiotensin II type 1 receptor (AT1R) blockers], may be responsible for ...
Yoshino Matsuo, Yasunori Suematsu, Sayo Tomita, Kohei Tashiro, Takashi Kuwano, Ken Kitajima, Shin-ichiro Miura   +6 more
doaj   +3 more sources

Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. [PDF]

BMJ Open, 2020
Russell JA, Marshall JC, Slutsky A, Murthy S, Sweet D, Lee T, Singer J, Patrick DM, Du B, Peng Z, Cheng M, Burns KD, Harhay MO.   +12 more
europepmc   +3 more sources